Drugs / BA1202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05909241 | Aug 2023 → Feb 2025 overdue | neoplastic disease or syndrome | Shandong Boan Biotechnology Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-26 | Luye Pharma Group Ltd. | Results 博安生物携CD3+ T-cell Engager专利平台及CEA/CD3研究成果亮相世界双特异性抗体峰会 luye.com ↗
临 床 前 研 究 数 据 显 示：BA1202对 肿 瘤 细 胞 具 有 高 杀 伤 力、可 显 著 减 少 细 胞 因 子 释 放、并 展 现 出 更 好 的 疗 效 潜 力. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-26 | Luye Pharma Group Ltd. | 博安生物携CD3+ T-cell Engager专利平台及CEA/CD3研究成果亮相世界双特异性抗体峰会 luye.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BA1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05909241 ↗ |
| Route | Intravenous | “BA1202 will be administered intravenously (IV)” NCT05909241 ↗ |